Login / Signup

Baseline risk factors determine lack of biochemical response after SVR in chronic hepatitis C patients treated with DAAs.

Frank TackeKlaus H W BoekerHartwig KlinkerRenate HeynePeter BuggischAnita PathilJohannes WiegandMarkus CornbergChristian LangeFlorian van BoemmelStefan ZeuzemStefan Mauss
Published in: Liver international : official journal of the International Association for the Study of the Liver (2019)
German Clinical Trials Register (DRKS; ID DRKS00009717).
Keyphrases
  • risk factors
  • clinical trial
  • phase ii
  • liver fibrosis
  • open label
  • phase iii
  • study protocol
  • double blind